Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2013

01.12.2013 | Original Article

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer

verfasst von: Giorgio Mauri, Claudia Chiodoni, Mariella Parenza, Ivano Arioli, Claudio Tripodo, Mario Paolo Colombo

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymphocyte depletion experiments demonstrated that the efficacy of CCL16/CpG/anti-IL-10R combination treatment relies upon CD8 T lymphocytes whereas CD4 T cells are dispensable. The results underlie the feasibility of echo-guided local immunotherapy of tumors located in visceral organs that are not easily accessible.
Literatur
1.
Zurück zum Zitat Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81PubMedCrossRef Drake CG, Jaffee E, Pardoll DM (2006) Mechanisms of immune evasion by tumors. Adv Immunol 90:51–81PubMedCrossRef
2.
Zurück zum Zitat Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399–415PubMedCrossRef Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 13:399–415PubMedCrossRef
3.
Zurück zum Zitat Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J et al (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:894–907PubMedCrossRef Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J et al (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:894–907PubMedCrossRef
4.
Zurück zum Zitat Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G et al (2003) Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. Clin Cancer Res 9:3546–3554PubMed Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G et al (2003) Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. Clin Cancer Res 9:3546–3554PubMed
5.
Zurück zum Zitat Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8:282–290PubMedCrossRef Palmer K, Hitt M, Emtage PC, Gyorffy S, Gauldie J (2001) Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity. Gene Ther 8:282–290PubMedCrossRef
6.
Zurück zum Zitat Reay J, Kim SH, Lockhart E, Kolls J, Robbins PD (2009) Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Ther 16:776–785PubMedCrossRef Reay J, Kim SH, Lockhart E, Kolls J, Robbins PD (2009) Adenoviral-mediated, intratumor gene transfer of interleukin 23 induces a therapeutic antitumor response. Cancer Gene Ther 16:776–785PubMedCrossRef
7.
Zurück zum Zitat Guiducci C, Di Carlo E, Parenza M, Hitt M, Giovarelli M et al (2004) Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 172:4026–4036PubMed Guiducci C, Di Carlo E, Parenza M, Hitt M, Giovarelli M et al (2004) Intralesional injection of adenovirus encoding CC chemokine ligand 16 inhibits mammary tumor growth and prevents metastatic-induced death after surgical removal of the treated primary tumor. J Immunol 172:4026–4036PubMed
8.
Zurück zum Zitat Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M et al (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71:5987–5997PubMedCrossRef Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M et al (2011) Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. Cancer Res 71:5987–5997PubMedCrossRef
9.
Zurück zum Zitat Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61:453–468PubMedCrossRef Rigamonti N, Bellone M (2012) Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol Immunother 61:453–468PubMedCrossRef
10.
Zurück zum Zitat Harrison T, Graham F, Williams J (1977) Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 77:319–329PubMedCrossRef Harrison T, Graham F, Williams J (1977) Host-range mutants of adenovirus type 5 defective for growth in HeLa cells. Virology 77:319–329PubMedCrossRef
11.
Zurück zum Zitat Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65:3437–3446PubMed Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65:3437–3446PubMed
12.
Zurück zum Zitat Tevethia SS, Lewis M, Tanaka Y, Milici J, Knowles B et al (1990) Dissection of H-2Db-restricted cytotoxic T-lymphocyte epitopes on simian virus 40 T antigen by the use of synthetic peptides and H-2Dbm mutants. J Virol 64:1192–1200PubMed Tevethia SS, Lewis M, Tanaka Y, Milici J, Knowles B et al (1990) Dissection of H-2Db-restricted cytotoxic T-lymphocyte epitopes on simian virus 40 T antigen by the use of synthetic peptides and H-2Dbm mutants. J Virol 64:1192–1200PubMed
13.
Zurück zum Zitat Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M et al (1999) Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 190:125–133PubMedCrossRef Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M et al (1999) Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 190:125–133PubMedCrossRef
14.
Zurück zum Zitat Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC et al (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78PubMedCrossRef Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC et al (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281:65–78PubMedCrossRef
15.
Zurück zum Zitat Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175–184PubMedCrossRef Homey B, Muller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175–184PubMedCrossRef
16.
Zurück zum Zitat Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC et al (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447–2463PubMedCrossRef Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC et al (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123:2447–2463PubMedCrossRef
Metadaten
Titel
Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer
verfasst von
Giorgio Mauri
Claudia Chiodoni
Mariella Parenza
Ivano Arioli
Claudio Tripodo
Mario Paolo Colombo
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2013
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-013-1486-7

Weitere Artikel der Ausgabe 12/2013

Cancer Immunology, Immunotherapy 12/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.